未知生产厂商
TY1 was developed at Cedars-Sinai as a synthetic version of a type of noncoding RNA, a molecule that regulates cellular processes. It was first used to reduce tissue damage in laboratory experiments addressing heart attacks and, after those results were reported, investigators sought to determine whether TY1 might have a similar effect on autoimmune disorders. TY1 was then tested in immune cells collected from patients with systemic sclerosis and in laboratory mice with a condition that mimics the disease; the study, conducted in a laboratory, was published in JCI Insight.
TY1 was developed at Cedars-Sinai as a synthetic version of a type of noncoding RNA, a molecule that regulates cellular processes. It was first used to reduce tissue damage in laboratory experiments addressing heart attacks and, after those results were reported, investigators sought to determine whether TY1 might have a similar effect on autoimmune disorders. TY1 was then tested in immune cells collected from patients with systemic sclerosis and in laboratory mice with a condition that mimics the disease; the study, conducted in a laboratory, was published in JCI Insight.
TY1 is a synthetic noncoding RNA that blocks the basic immune system pathway driving systemic sclerosis, attenuating the cGAS/STING pathway and thereby reducing inflammation and DNA damage in immune cells.
共 1 项相关疾病
